Anakinra
| |
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 143090-92-0 |
| ATC kod | L04AC03 |
| DrugBank | DB00026 |
| ChEMBL[1] | CHEMBL1201570 
|
| Hemijski podaci | |
| Formula | C759H1186N208O232S10 |
| Mol. masa | 17,257.6 |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 4 - 6 h |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Subkutano |
Anakinra (Kineret) je lek koji se koristi za lečenje reumatoidnog artritisa.[2] Anakinra je rekombinantni, neglikozilirani antagornist ljudskig interleukin 1 receptora (IL-1Ra). Razlika između njega i prirodnog liganda je u tome što anakinra dva dodatna metioninska ostatka na amino terminusu. On se proizvodi koristeći E. coli ekspresioni sistem. Anakinra se sastoji od 153 aminokiselina. FDA je odobrila upotrebu ovog leka novembera 2001.[3][4][5][6]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Fleischmann RM, Tesser J, Schiff MH, et al. (August 2006). „Safety of extended treatment with anakinra in patients with rheumatoid arthritis”. Annals of the rheumatic diseases 65 (8): 1006–12. DOI:10.1136/ard.2005.048371. PMC 1798263. PMID 16396977.
- ↑ Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. PMID 11752352
- ↑ Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J; Société Francophone pour l a Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):281-2. DB00026 PMID 17947302
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
